Pubblicazioni

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

2015 - NEPHROLOGY DIALYSIS TRANSPLANTATION

Goldsmith, D.; Covic, A.; Vervloet, M.; Cozzolino, M.; Nistor, I.; Brandenburg, V.; Bover, J.; Evenepoel, P.; Massy, Z.; Mazzaferro, S.; Urena-Torres, P.; Abramowicz, D.; Bolignano, D.; Cannata Andia, G.; Cochat, P.; Delvecchio, L.; Drechsler, C.; Eckardt, K. U.; Fouque, D.; Fox, J.; Haller, M.; Heimburger, O.; Jager, K. J.; Lindley, E.; Marti Monros, A. M.; Nagler, E.; Oberbauer, R.; Spasovski, G.; Tattersall, J.; Van Biesen, W.; Vander Veer, S.; Vanholder, R.; Wanner, C.; Wheeler, D.; Whithers, W.; Wiecek, A.; Zoccali, C.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4). A double-blind, multicentre, phase 3, randomised, placebo-controlled trial

2015 - THE LANCET ONCOLOGY

Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C; Hart, Lowell L; Jones, Robert; Mcdermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; Maclean, David B; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I; Dreicer, Robert; Webb, Iain J; de Wit, Ronald; Collaborators, ; Tubaro, Andrea